💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Investors unimpressed with VistaGen update on AV-101; shares down 16%

Published 01/30/2018, 10:39 AM
© Reuters.  Investors unimpressed with VistaGen update on AV-101; shares down 16%
VTGN
-
  • Nano cap VistaGen Therapeutics (NASDAQ:VTGN) is down 16% on modestly higher volume on the heels of a presentation yesterday by CEO Shawn Singh at NobelCon14. Investors appear disappointed with the timeline for lead candidate AV-101 (4-chlorokynurenine), an NMDA receptor antagonist prodrug that he says lacks the unwanted side effects of ketamine.
  • The company is initially targeting second-line treatment of major depressive disorder (MDD) with AV-101. Topline data from a Phase 2 study should be available in H1 2019.
  • Other proposed indications for AV-101 are neuropathic pain, a condition affecting 5% or more of Americans and Parkinson's disease levodopa-induced dyskinesia. Phase 2 studies are next up, albeit expected to start in H2 2019.
  • Now read: Dynavax (DVAX) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.